Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy
Davide Vito Moretti, Giuliano Binetti, Orazio Zanetti, Giovanni Battista Frisoni IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, ItalyAbstract: Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson&r...
Guardado en:
Autores principales: | Moretti DV, Binetti G, Zanetti O, Frisoni GB |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ed132552078544d8944ec36a99bf280e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Restless legs syndrome: differential diagnosis and management with rotigotine
por: Giovanni Merlino, et al.
Publicado: (2009) -
Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor
por: Kathryn M. Miller, et al.
Publicado: (2021) -
Comparative proteomic analysis highlights metabolic dysfunction in α-synucleinopathy
por: Souvarish Sarkar, et al.
Publicado: (2020) -
Il-10 signaling reduces survival in mouse models of synucleinopathy
por: Samuel G. Cockey, et al.
Publicado: (2021) -
Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
por: Ariadna Laguna, et al.
Publicado: (2021)